Post by Admin on Mar 24, 2024 18:10:47 GMT
Concerns regarding Transfusions of Blood Products Derived from Genetic Vaccine Recipients and Proposals for Specific Measures
Abstract: The coronavirus pandemic was declared by the World Health Organization (WHO) in 2020, and a global genetic vaccination program has been rapidly implemented as a fundamental solution. However, many countries around the world have reported that so-called genetic vaccines, such as those using modified mRNA encoding the spike protein and lipid nanoparticles as the drug delivery system, have resulted in post-vaccination thrombosis and subsequent cardiovascular damage, as well as a wide variety of diseases involving all organs and systems, including the nervous system. In this article, based on these circumstances and the volume of evidence that has recently come to light, we call the attention of medical professionals to the various risks associated with blood transfusions using blood products derived from people who have suffered from long COVID and from genetic vaccine recipients, including those who have received mRNA vaccines, and we make proposals regarding specific tests, testing methods, and regulations to deal with these risks. We expect that this proposal will serve as a basis for discussion on how to address post-vaccination syndrome and its consequences following these genetic vaccination programs.
In addition to thrombosis, individuals who have received multiple doses of a genetic vaccine may have multiple exposures to the same antigen within a brief period, thereby being imprinted with a preferential immune response to that antigen [63,64]. This phenomenon, called original antigenics in or immune imprinting, has caused COVID-19 vaccine recipients to become more susceptible to contracting COVID-19 [65].
This raises concern that alterations in immune function due to immune imprinting and immunoglobulin class switching to IgG4 may also occur in genetic vaccine recipients. This may increase the risk of serious illness due to opportunistic infections or pathogenic viruses that would not normally be a problem if the immune system were normal [76–82]
In summary, there is an undeniable risk that patients may experience some problems if they receive blood products derived from blood collected in, at least, a brief deferral period after genetic vaccination. Although it is unknown at present whether secondary damage is caused by transfusion
of blood products derived from genetic vaccine recipients, it is necessary for medical institutions and administrative organizations to respond and investigate cooperatively, keeping various possibilities in mind, because mechanisms such as the toxicity of the spike protein itself and the effects of LNPs and modified mRNA on the immune response have not been fully elucidated and are still under study.
Abstract: The coronavirus pandemic was declared by the World Health Organization (WHO) in 2020, and a global genetic vaccination program has been rapidly implemented as a fundamental solution. However, many countries around the world have reported that so-called genetic vaccines, such as those using modified mRNA encoding the spike protein and lipid nanoparticles as the drug delivery system, have resulted in post-vaccination thrombosis and subsequent cardiovascular damage, as well as a wide variety of diseases involving all organs and systems, including the nervous system. In this article, based on these circumstances and the volume of evidence that has recently come to light, we call the attention of medical professionals to the various risks associated with blood transfusions using blood products derived from people who have suffered from long COVID and from genetic vaccine recipients, including those who have received mRNA vaccines, and we make proposals regarding specific tests, testing methods, and regulations to deal with these risks. We expect that this proposal will serve as a basis for discussion on how to address post-vaccination syndrome and its consequences following these genetic vaccination programs.
In addition to thrombosis, individuals who have received multiple doses of a genetic vaccine may have multiple exposures to the same antigen within a brief period, thereby being imprinted with a preferential immune response to that antigen [63,64]. This phenomenon, called original antigenics in or immune imprinting, has caused COVID-19 vaccine recipients to become more susceptible to contracting COVID-19 [65].
This raises concern that alterations in immune function due to immune imprinting and immunoglobulin class switching to IgG4 may also occur in genetic vaccine recipients. This may increase the risk of serious illness due to opportunistic infections or pathogenic viruses that would not normally be a problem if the immune system were normal [76–82]
In summary, there is an undeniable risk that patients may experience some problems if they receive blood products derived from blood collected in, at least, a brief deferral period after genetic vaccination. Although it is unknown at present whether secondary damage is caused by transfusion
of blood products derived from genetic vaccine recipients, it is necessary for medical institutions and administrative organizations to respond and investigate cooperatively, keeping various possibilities in mind, because mechanisms such as the toxicity of the spike protein itself and the effects of LNPs and modified mRNA on the immune response have not been fully elucidated and are still under study.